PapersFlow Research Brief
Pancreatic and Hepatic Oncology Research
Research Guide
What is Pancreatic and Hepatic Oncology Research?
Pancreatic and Hepatic Oncology Research is the study of the biology, diagnosis, and treatment of cancers arising in the pancreas and hepatobiliary system, spanning prevention and screening, imaging and pathology, systemic therapy, surgery, and mechanisms of metastasis (especially to the liver).
Pancreatic and hepatic oncology research integrates surgical outcomes research, quantitative imaging, tumor-microenvironment biology, and systemic therapy trials to improve survival and quality of life in pancreatic and hepatobiliary malignancies. This topic cluster contains 148,349 works (5-year growth: N/A), reflecting a large literature that ranges from complication grading in surgery to randomized chemotherapy trials and immunotherapy development. Highly cited anchors include standardized surgical complication reporting (Clavien et al., 2009, "The Clavien-Dindo Classification of Surgical Complications"), quantitative imaging feature extraction (Gillies et al., 2015, "Radiomics: Images Are More than Pictures, They Are Data"), and metastatic pancreatic cancer chemotherapy trials comparing multi-agent therapy with gemcitabine (Conroy et al., 2011, "FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer").
Topic Hierarchy
Research Sub-Topics
Gemcitabine in Pancreatic Cancer
This sub-topic evaluates gemcitabine-based regimens, resistance pathways, and biomarkers for response. Researchers conduct phase III trials and pharmacodynamic studies.
Pancreatic Cancer Tumor Microenvironment
This sub-topic dissects stromal desmoplasia, immune infiltration, and hypoxia in PDAC progression. Researchers target TME components to enhance drug delivery and immunity.
Pancreatic Cancer Genomic Analyses
This sub-topic profiles KRAS, SMAD4, and TP53 mutations via WES and scRNA-seq in PDAC. Researchers identify actionable alterations and evolutionary dynamics.
Neoadjuvant Therapy in Pancreatic Cancer
This sub-topic assesses preoperative chemo-radiotherapy for borderline resectable PDAC. Researchers measure pathological response and survival benefits.
Stromal Biology in Pancreatic Cancer
This sub-topic studies cancer-associated fibroblasts, ECM remodeling, and matricellular proteins in PDAC. Researchers develop stromal-depleting agents to normalize TME.
Why It Matters
Clinical decisions in pancreatic and hepatobiliary cancers often trade off morbidity, symptom control, and survival, so reproducible endpoints and validated regimens directly affect patient care. For surgery-focused studies and trials, Clavien et al. (2009) in "The Clavien-Dindo Classification of Surgical Complications" provided a globally applicable complication grading system that enables comparable reporting across centers and trials, which is essential when evaluating interventions in high-risk operations typical of hepato-pancreatic-biliary oncology. For systemic therapy in metastatic pancreatic adenocarcinoma, Conroy et al. (2011) in "FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer" and Von Hoff et al. (2013) in "Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine" established widely used chemotherapy backbones; Burris et al. (1997) in "Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial." is a key reference for gemcitabine’s role in advanced disease and symptom-related benefit. Imaging-driven risk stratification and response assessment are increasingly central because treatment selection depends on staging and disease biology; Gillies et al. (2015) in "Radiomics: Images Are More than Pictures, They Are Data" framed how high-throughput quantitative imaging features can be treated as data for modeling, a concept that underpins many oncology imaging pipelines. At the population level, Rahib et al. (2014) in "Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States" connected pancreatic and liver cancer to future U.S. burden projections, motivating health-system planning and prioritization of early detection and more effective therapies.
Reading Guide
Where to Start
Start with Clavien et al. (2009), "The Clavien-Dindo Classification of Surgical Complications", because it defines a shared language for morbidity endpoints that you will need to interpret surgical and multimodality pancreatic/hepatic oncology studies.
Key Papers Explained
Clavien et al. (2009), "The Clavien-Dindo Classification of Surgical Complications", provides standardized perioperative outcome reporting, which is essential when comparing strategies that combine surgery with systemic therapy. Burris et al. (1997), "Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.", establishes gemcitabine as a foundational advanced-disease regimen and frames clinical benefit as a key endpoint. Conroy et al. (2011), "FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer", and Von Hoff et al. (2013), "Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine", then define two major systemic therapy backbones used for metastatic pancreatic cancer, enabling comparative thinking about efficacy-toxicity tradeoffs. Gillies et al. (2015), "Radiomics: Images Are More than Pictures, They Are Data", connects imaging to quantitative modeling and complements these clinical trials by motivating data-driven stratification and response assessment; Massagué (1998), "TGF-β SIGNAL TRANSDUCTION", supplies mechanistic context often invoked when interpreting tumor microenvironment and stromal biology themes mentioned in the topic description.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent directions in the provided list emphasize metastasis biology and organ-specific recurrence, exemplified by "Cellular states associated with metastatic organotropism and survival in patients with pancreatic ductal adenocarcinoma" (2025), which analyzed 744 patients with resected pancreatic ductal adenocarcinoma and contrasted outcomes for initial isolated liver-metastatic recurrence (n=100) versus initial isolated lung-metastatic recurrence (n=31). Mechanistic liver–pancreas cross-talk is also foregrounded by "Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via the macrophage migration inhibitory factor-CD44 axis" (2026). Prognostic modeling that explicitly centers the tumor microenvironment appears in "Hepato Pancreatic Biliary Cancers" (2026), described as an lncRNA-based prognostic model for pancreatic cancer centered on the TME with exploratory LLPS connections, and immuno-metabolic integration is represented by "Frontiers | Immuno-metabolic Approaches for the Treatment of Hepatobiliary and Pancreatic Tumors" (2025).
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | The Clavien-Dindo Classification of Surgical Complications | 2009 | Annals of Surgery | 10.8K | ✕ |
| 2 | Radiomics: Images Are More than Pictures, They Are Data | 2015 | Radiology | 7.8K | ✕ |
| 3 | TGF-β SIGNAL TRANSDUCTION | 1998 | Annual Review of Bioch... | 7.6K | ✕ |
| 4 | FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer | 2011 | New England Journal of... | 7.5K | ✓ |
| 5 | Pancreatic Cancer | 2000 | — | 7.2K | ✕ |
| 6 | Projecting Cancer Incidence and Deaths to 2030: The Unexpected... | 2014 | Cancer Research | 7.0K | ✕ |
| 7 | Classification of acute pancreatitis—2012: revision of the Atl... | 2012 | Gut | 6.7K | ✓ |
| 8 | Increased Survival in Pancreatic Cancer with nab-Paclitaxel pl... | 2013 | New England Journal of... | 6.4K | ✕ |
| 9 | Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer | 2015 | New England Journal of... | 6.1K | ✓ |
| 10 | Improvements in survival and clinical benefit with gemcitabine... | 1997 | Journal of Clinical On... | 5.8K | ✕ |
In the News
The Lustgarten Foundation Announces Landmark Year of ...
UNIONDALE, NY, Aug 15, 2025 — The Lustgarten Foundation, the nation’s largest private funder of pancreatic cancer research, today announced a landmark year of funding, awarding ten new grants to re...
The Lustgarten Foundation Announces Landmark Year of ...
UNIONDALE, N.Y.,Sept. 15, 2025/PRNewswire/ -- The Lustgarten Foundation, the nation's largest private funder of pancreatic cancer research, today announced a landmark year of funding, awarding ten ...
Perseverance and Progress in Pancreatic Cancer Care
**New Grant Funding Aims to Quell Pancreatic Cancer with Immunotherapy** June 27, 2024 \| 7 min. read ### Categories
UCLA scientists develop one-product-fits-all ...
With all preclinical studies now complete, the team is preparing to submit applications to the Food and Drug Administration to begin clinical trials.
Vaccine for pancreatic and colorectal cancer: phase I AMPLIFY-201 trial
Long-term follow-up results of the phase I AMPLIFY-201 clinical trial (NCT04853017) have been published in*Nature Medicine*. The study is investigating the use of the cancer vaccine ELI-002 2P in 2...
Code & Tools
MINDS is a framework designed to integrate multimodal oncology data. It queries and integrates data from multiple sources, including clinical data,...
HoneyBee is a comprehensive multimodal AI framework designed specifically for oncology research and clinical applications. It seamlessly integrates...
An automated framework for comprehensive multi-omic analysis of gene expression and clonetype immune repertoire at a single-cell level ### License...
## Repository files navigation # Pancreatic cancer screening in patients with new-onset diabetes _A Novel Multimodal Approach to Pancreatic Cance...
Recent Preprints
Hepato Pancreatic Biliary Cancers
Original Research Published on 23 Jan 2026 ## lncRNA-based prognostic model for pancreatic cancer centered on the TME with exploratory LLPS connections inGastrointestinal Cancers: Hepato Pancreatic...
Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via the macrophage migration inhibitory factor-CD44 axis
Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via the macrophage migration inhibitory factor-CD44 axis Download PDF Download P...
Frontiers | Immuno-metabolic Approaches for the Treatment of Hepatobiliary and Pancreatic Tumors
**Development of a Nomogram Integrating Immune Checkpoints, 1 Fibrosis indicators, and Clinicopathological Characteristics to 2 Predict Overall Survival in Pancreatic Cancer: A Retrospective 3 Anal...
Cellular states associated with metastatic organotropism and survival in patients with pancreatic ductal adenocarcinoma
Most patients with localized pancreatic ductal adenocarcinoma (PDAC) experience recurrence after resection. Analysis of 744 patients with resected PDAC revealed that patients with initial isolated ...
Deciphering the liver's role in pancreatic cancer metastasis
The liver frequently serves as a site for metastasis in pancreatic ductal adenocarcinoma (PDAC), attributable to its extensive blood supply and supportive microenvironment, which fosters the format...
Latest Developments
Recent developments in pancreatic and hepatic oncology research as of February 2026 include advances in personalized neoantigen vaccines, targeted therapies for RAS mutations, and immunotherapy approaches, with notable progress in early detection, molecular targeting, and clinical trials such as autologous T cell therapy and NK-cell therapy (nature.com, pancan.org, mdanderson.org, cancer.gov, and nature.com, all from late 2025 to early 2026).
Sources
Frequently Asked Questions
What is the scope of Pancreatic and Hepatic Oncology Research?
Pancreatic and hepatic oncology research spans tumor biology (including microenvironmental signaling), diagnosis and imaging, surgical management and complications, systemic therapy (chemotherapy and immunotherapy), and patterns of recurrence and metastasis. The provided topic description explicitly emphasizes surgical complications, gemcitabine-based regimens, tumor microenvironment and stromal biology, genomic analyses, neoadjuvant therapy, immunotherapy, hospital volume effects on outcomes, and pancreatic cyst prevalence.
How are surgical complications standardized and reported in hepato-pancreatic-biliary oncology studies?
Clavien et al. (2009) in "The Clavien-Dindo Classification of Surgical Complications" reported a 5-year evaluation supporting the classification’s validity and worldwide applicability across surgical fields. Using a common grading scheme enables more comparable reporting of morbidity across centers and trials in high-risk pancreatic and liver operations.
Which chemotherapy regimens are most central for metastatic pancreatic cancer in the provided literature?
Conroy et al. (2011) in "FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer" directly compared a multi-agent regimen with gemcitabine in metastatic disease. Von Hoff et al. (2013) in "Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine" evaluated a gemcitabine-based combination and reported improved outcomes with increased peripheral neuropathy and myelosuppression, while Burris et al. (1997) in "Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial." is a foundational trial for gemcitabine in advanced pancreas cancer.
How is quantitative imaging used to support pancreatic and liver cancer research?
Gillies et al. (2015) in "Radiomics: Images Are More than Pictures, They Are Data" described radiomics as high-throughput extraction of quantitative image features enabled by pattern recognition tools and larger datasets. This framing supports imaging-based modeling for tasks such as risk stratification, tumor characterization, and treatment response assessment when imaging is central to staging and follow-up.
Which biological pathway paper in the list is most relevant to tumor microenvironment and stromal biology?
Massagué (1998) in "TGF-β SIGNAL TRANSDUCTION" synthesized a network view of TGF-β signaling involving receptor serine/threonine kinases and downstream mediators. Because TGF-β signaling is a common axis in tissue homeostasis and cancer-associated stromal interactions, it is frequently used as a mechanistic reference point when studying microenvironmental regulation in pancreatic and hepatobiliary tumors.
What do the provided data say about future disease burden for liver and pancreas cancers in the United States?
Rahib et al. (2014) in "Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States" projected U.S. incidence and deaths for common cancers through 2030 using demographic change and average annual percentage changes in incidence and death rates. The paper explicitly highlighted liver and pancreas cancers as contributors to an unexpected future burden, supporting prioritization of prevention, early detection, and more effective systemic therapies.
Open Research Questions
- ? Which radiomic feature sets and validation designs, consistent with the principles in "Radiomics: Images Are More than Pictures, They Are Data" (2015), generalize across institutions for predicting pancreatic cancer treatment response?
- ? How can TGF-β pathway mechanisms summarized in "TGF-β SIGNAL TRANSDUCTION" (1998) be operationalized into clinically testable strategies that modulate stromal biology without unacceptable toxicity in pancreatic and hepatobiliary tumors?
- ? Which patient subgroups derive the most net benefit (balancing efficacy and toxicity) when choosing between regimens studied in "FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer" (2011) and "Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine" (2013)?
- ? How should complication endpoints be selected and harmonized using "The Clavien-Dindo Classification of Surgical Complications" (2009) to compare perioperative strategies across high-volume and low-volume centers in hepato-pancreatic-biliary oncology?
- ? Which mechanisms drive liver-dominant recurrence patterns after resection, and how should they shape surveillance and adjuvant strategies in pancreatic ductal adenocarcinoma, given the clinical heterogeneity highlighted in "Cellular states associated with metastatic organotropism and survival in patients with pancreatic ductal adenocarcinoma" (2025)?
Recent Trends
The provided recent papers emphasize liver-directed metastasis and recurrence heterogeneity as a clinical and biological focus area. "Cellular states associated with metastatic organotropism and survival in patients with pancreatic ductal adenocarcinoma" analyzed 744 resected patients and reported worse overall survival for initial isolated liver-metastatic recurrence (n=100) compared with initial isolated lung-metastatic recurrence (n=31), reinforcing organotropism as a stratifier for outcomes and study design.
2025Mechanistic coupling between liver disease and pancreatic cancer progression is highlighted by "Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via the macrophage migration inhibitory factor-CD44 axis" , while prognostic and immunologic modeling trends are represented by "Hepato Pancreatic Biliary Cancers" (2026) (lncRNA/TME-centered prognostic model) and "Frontiers | Immuno-metabolic Approaches for the Treatment of Hepatobiliary and Pancreatic Tumors" (2025) (nomogram integrating immune checkpoints and fibrosis indicators).
2026Research Pancreatic and Hepatic Oncology Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Pancreatic and Hepatic Oncology Research with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers